SCHEDULE 13G/A 0001948604 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/31/2025 0001885522 Neumora Therapeutics, Inc. 640979100 260 Arsenal Place Suite 1 Watertown MA 02472 Rule 13d-1(c) K2 HealthVentures Equity Trust LLC DE 0 8997035 0 8997035 8997035 N 5.01 OO Parag Shah X1 0 8997035 0 8997035 8997035 N 5.01 IN HC Anup Arora X1 0 8997035 0 8997035 8997035 N 5.01 IN HC Neumora Therapeutics, Inc. 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472 This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. K2 HealthVentures Equity Trust LLC ("K2HV Equity"); ii. Parag Shah ("Mr. Shah"); and iii. Anup Arora ("Mr. Arora"). This Statement on Schedule 13G relates to 1,055,899 shares of Common Stock held directly by K2HV Equity and an aggregate 7,941,136 shares of Common Stock K2HV Equity has the right to acquire within 60 days upon conversion of the remaining balance of the Issuer's outstanding debt obligations to K2HV Equity under the Loan and Security Agreement, dated as of May 9, 2025, between the Issuer and K2HV Equity, as amended by the First Amendment to Loan and Security Agreement, dated as of November 4, 2025, including (i) 6,895,374 shares of Common Stock that are issuable at a conversion price of the lesser of $0.8774 per share and the lowest effective price per share of the Issuer's next equity financing (the "Original Conversion Shares"), and (ii) 1,045,762 shares of Common Stock that are issuable at a conversion price of $2.3906 per share (the "Amendment Conversion Shares" and, together with the Original Conversion Shares, the "Conversion Shares"). For purposes of this Schedule 13G, we have assumed a conversion price of $0.8774 per share for the Original Conversion Shares. K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it holds directly and has the right to acquire upon conversion of the Conversion Shares, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns. The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116. K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America. Y As of December 31, 2025, each of the Reporting Persons may be deemed the beneficial owner of 8,997,035 shares of Common Stock. This amount consists of (i) 1,055,899 shares of Common Stock directly held by K2HV Equity and (ii) an aggregate 7,941,136 shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares. As of December 31, 2025, each of the Reporting Persons may be deemed the beneficial owner of approximately 5.01% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on the sum of (i) 167,089,114 shares of Common Stock outstanding as of November 1, 2025, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2025, (ii) 2,849,327 shares of Common Stock that became outstanding following K2HV Equity's conversion of Original Conversion Shares on November 20, 2025, (iii) 1,652,609 shares of Common Stock that became outstanding following K2HV Equity's conversion of Original Conversion Shares on December 11, 2025, and (iv) an aggregate 7,941,136 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares, which Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended. 0 8,997,035 0 8,997,035 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. K2 HealthVentures Equity Trust LLC /s/ Anup Arora 02/17/2026 Parag Shah /s/ Parag Shah 02/17/2026 Anup Arora /s/ Anup Arora 02/17/2026